Ur Metser1, Jill Dudebout2, Tara Baetz2, David C Hodgson3, Deanna L Langer4, Pamela MacCrostie4, Victor Mak5, Noam Tau1. 1. Joint Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada. 2. Department of Oncology, Cancer Centre of Southeastern Ontario, Queen's University, Kingston, Ontario, Canada. 3. Department of Radiation Oncology, University of Toronto, and Radiation Medicine Program, Princess Margaret Hospital, Toronto, Ontario, Canada. 4. Cancer Imaging, Clinical Programs and Quality Initiatives, Cancer Care Ontario, Toronto, Ontario, Canada. 5. Cancer Analytics, Cancer Care Ontario, Toronto, Ontario, Canada.
Abstract
BACKGROUND: To measure the clinical impact of pretreatment fludeoxyglucose positron emission tomography/computed tomography (PET/CT) on the staging and management of apparent limited stage indolent lymphoma being considered for curative radiation therapy. METHODS: We conducted a prospective multicenter registry study that included 197 patients accrued between May 1, 2012, and December 31, 2015. Pre-PET/CT stage, determined by clinical and CT data, was documented. If pre-PET/CT stage was indeterminate, a stage was assigned to the patient by the referring oncologist according to best clinical judgment and treatment intent. After PET/CT, revised stage and planned management were recorded and compared with data on actual treatment received available through provincial databases (n = 155). RESULTS: PET/CT resulted in the upstaging of 47 (23.9%) patients with presumed limited stage disease (stage I-II) to advanced stage disease (stage III-IV) (P < .0001). Ten (5.1%) patients were downstaged by PET/CT, 4 of whom migrated from advanced to limited stage disease. Twenty-eight (14.2%) patients with a specific pre-PET/CT stage had equivocal PET/CT findings that required further evaluation to confirm disease extent. After PET/CT, 95 (61.3%) patients were planned to receive active treatment. Of the 59 patients planned for radiotherapy alone post-PET/CT, 34 (57.6%) received this treatment (P = .002), and nearly 80% of them (n = 27) had confirmed limited stage disease. CONCLUSION: PET/CT has a significant impact on staging and management in patients with apparent limited stage indolent lymphoma who are being considered for curative radiotherapy. PET/CT should be routinely incorporated into the workup of these patients. Cancer 2017;123:2860-66.
BACKGROUND: To measure the clinical impact of pretreatment fludeoxyglucose positron emission tomography/computed tomography (PET/CT) on the staging and management of apparent limited stage indolent lymphoma being considered for curative radiation therapy. METHODS: We conducted a prospective multicenter registry study that included 197 patients accrued between May 1, 2012, and December 31, 2015. Pre-PET/CT stage, determined by clinical and CT data, was documented. If pre-PET/CT stage was indeterminate, a stage was assigned to the patient by the referring oncologist according to best clinical judgment and treatment intent. After PET/CT, revised stage and planned management were recorded and compared with data on actual treatment received available through provincial databases (n = 155). RESULTS: PET/CT resulted in the upstaging of 47 (23.9%) patients with presumed limited stage disease (stage I-II) to advanced stage disease (stage III-IV) (P < .0001). Ten (5.1%) patients were downstaged by PET/CT, 4 of whom migrated from advanced to limited stage disease. Twenty-eight (14.2%) patients with a specific pre-PET/CT stage had equivocal PET/CT findings that required further evaluation to confirm disease extent. After PET/CT, 95 (61.3%) patients were planned to receive active treatment. Of the 59 patients planned for radiotherapy alone post-PET/CT, 34 (57.6%) received this treatment (P = .002), and nearly 80% of them (n = 27) had confirmed limited stage disease. CONCLUSION: PET/CT has a significant impact on staging and management in patients with apparent limited stage indolent lymphoma who are being considered for curative radiotherapy. PET/CT should be routinely incorporated into the workup of these patients. Cancer 2017;123:2860-66.
Authors: Sweet Ping Ng; Richard Khor; Mathias Bressel; Michael MacManus; John F Seymour; Rodney J Hicks; Andrew Wirth Journal: Eur J Nucl Med Mol Imaging Date: 2018-08-07 Impact factor: 9.236
Authors: Christina Pfannenberg; Brigitte Gueckel; Lisa Wang; Sergios Gatidis; Susann-Cathrin Olthof; Werner Vach; Matthias Reimold; Christian la Fougere; Konstantin Nikolaou; Peter Martus Journal: Eur J Nucl Med Mol Imaging Date: 2018-09-29 Impact factor: 9.236
Authors: Joshua W D Tobin; Gabrielle Rule; Katherine Colvin; Lourdes Calvente; David Hodgson; Stephen Bell; Chengetai Dunduru; James Gallo; Erica S Tsang; Xuan Tan; Jonathan Wong; Jessica Pearce; Robert Campbell; Shao Tneh; Sophie Shorten; Melissa Ng; Tara Cochrane; Constantine S Tam; Emad Abro; Eliza Hawkes; Georgina Hodges; Roopesh Kansara; Dipti Talaulikar; Michael Gilbertson; Anna M Johnston; Kerry J Savage; Diego Villa; Kirk Morris; Sumi Ratnasingam; Wojt Janowski; Robert Kridel; Chan Y Cheah; Michael MacManus; Nicholas Matigian; Peter Mollee; Maher K Gandhi; Greg Hapgood Journal: Blood Adv Date: 2019-10-08
Authors: Connie L Batlevi; Fushen Sha; Anna Alperovich; Ai Ni; Katy Smith; Zhitao Ying; John F Gerecitano; Paul A Hamlin; Steve M Horwitz; Erel Joffe; Anita Kumar; Matthew J Matasar; Alison J Moskowitz; Craig H Moskowitz; Ariela Noy; Colette Owens; Lia M Palomba; David Straus; Gottfried von Keudell; Andrew D Zelenetz; Venkatraman E Seshan; Stefano Luminari; Luigi Marcheselli; Massimo Federico; Anas Younes Journal: Eur J Cancer Date: 2020-01-08 Impact factor: 9.162
Authors: Gary L Griffiths; Crystal Vasquez; Freddy Escorcia; Jeff Clanton; Liza Lindenberg; Esther Mena; Peter L Choyke Journal: Adv Drug Deliv Rev Date: 2021-12-20 Impact factor: 15.470
Authors: Anna Zoellner; Klaus Herfarth; Michael Herold; Wolfram Klapper; Nicole Skoetz; Wolfgang Hiddemann Journal: Dtsch Arztebl Int Date: 2021-04-30 Impact factor: 8.251
Authors: Fushen Sha; Michelle Okwali; Anna Alperovich; Philip C Caron; Lorenzo Falchi; Audrey Hamilton; Paul A Hamlin; Steven M Horwitz; Erel Joffe; Niloufer Khan; Anita Kumar; Matthew J Matasar; Alison J Moskowitz; Ariela Noy; Colette Owens; Lia M Palomba; Ildefonso Rodriguez-Rivera; David Straus; Gottfried von Keudell; Andrew D Zelenetz; Joachim Yahalom; Ahmet Dogan; Heiko Schöder; Venkatraman E Seshan; Gilles Salles; Anas Younes; Connie L Batlevi Journal: Blood Cancer J Date: 2022-02-10 Impact factor: 11.037
Authors: Andrea C Lo; Lyndon P James; Anca Prica; Adam Raymakers; Stuart Peacock; Melody Qu; Alex V Louie; Kerry J Savage; Laurie H Sehn; David Hodgson; Joanna C Yang; Hans T T Eich; Andrew Wirth; M G Myriam Hunink Journal: J Nucl Med Date: 2021-08-19 Impact factor: 10.057